LumiraDx has secured $14.2m funding from the Bill & Melinda Gates Foundation to support the ongoing development of its point-of-care molecular test for tuberculosis (TB).

The test is being developed for use with the LumiraDx multi-assay Platform and to provide accurate results at a low price.

It helps clinicians to start providing proper treatment and manage patient properly to increase health outcomes and lower further spread of infection.

The company claimed that the LumiraDx Platform is the only point-of-care instrument that supports molecular and immunoassay technologies and run a range of sample types.

LumiraDx CEO Ron Zwanziger said: “The advancement of our TB molecular test signifies an important step forward in LumiraDx’s mission to increase access to accurate and affordable testing worldwide as well as an important step forward in our molecular testing technology.

“The support from the Gates Foundation is critical in our development of the TB test and ensuring it reaches communities where access to testing is most challenged. The availability of these immediate results can be game-changing.”

The gap between the people infected with TB and the diagnosis widened in 2020 and 2021 compared to 2019 to more than four million annually, as per the World Health Organization’s (WHO) 2022 Global Tuberculosis Report.

LumiraDx stated that the new molecular TB test is designed to fill these gaps and requirements in the TB testing market and increase access to disease testing.

The point-of-care TB test is being developed to offer testing at a low price and to include a tongue swab sample that makes the test easier for the majority of patients.

Furthermore, the company has already commenced pre-clinical studies of the TB molecular test in Africa.

Last month, LumiraDx launched new C-Reactive Protein (CRP) point of care antigen test in India.